A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...

Stanford University-led researchers report that tumor cells hijack mitochondria from immune cells, reducing anti-tumor immune ...

Early data of Waldenström’s non-Hodgkin lymphoma patients enrolled in a trial testing Immunitybio Inc.’s off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK), ...

Despite 700% net product revenue growth to $113 million, ImmunityBio's high debt load and unprofitability remain significant ...

The company is restarting its solid tumor program with the Phase I trial after the company paused it to focus on blood cancer.

CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...

A new cancer therapy wakes up immune cells inside tumors and turns them against cancer.

Regular exercise supports immune health by improving the circulation of your immune cells and reducing inflammation, but ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as NAFLD, represents the most prevalent liver disorder globally, ...

GTB-5550 represents GT Biopharma's third NK cell engager advancing toward clinical development, targeting B7-H3, a protein prevalent across breast, lung, ovarian, pancreatic, prostate, bladder, and ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...